If you wish to report an adverse event or product complaint, please call 1-800-LILLYRX (1-800-545-5979)
Mounjaro™ (tirzepatide) injection
2.5 mg/5 mg/7.5 mg/10 mg/12.5 mg/15 mg
This information is provided in response to your request. Resources may contain information about doses, uses, formulations and populations different from product labeling. See Prescribing Information above, if applicable.
Can tirzepatide be used to treat latent autoimmune diabetes in adults (LADA) also known as type 1.5 diabetes?
No information is available on the use of tirzepatide to treat people with LADA.
See important safety information, including boxed warning, in the attached prescribing information.
LADA (Type 1.5 Diabetes)
Tirzepatide is not indicated to treat latent autoimmune diabetes in adults (LADA) also known as type 1.5 diabetes.
Currently, Eli Lilly and company does not have any planned tirzepatide clinical trials in people with LADA.
Enclosed Prescribing Information
Date of Last Review: May 13, 2022